Antiretroviral therapy reduces the rate of hepatic decompensation among HIV-and hepatitis C virus-coinfected veterans

Clinical Infectious Diseases

Volumn 58, Issue 5, 2014, Pages 719-727

  Anderson, Jeffrey P ^a   Tchetgen Tchetgen, Eric J ^a,b   Lo Re, Vincent ^c,d   Tate, Janet P ^e,f   Williams, Paige L ^b   Seage, George R ^a   Horsburgh, C Robert ^g,h   Lim, Joseph K ^e,f   Goetz, Matthew Bidwell ^i,j   Rimland, David ^k,l   Rodriguez Barradas, Maria C ^c,m   Butt, Adeel A ^n,o   Klein, Marina B ^p   Justice, Amy C ^e,f  

^a Departments of Biostatistics and Epidemiology   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k ATLANTA VA MEDICAL CENTER   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^o SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^p ROYAL VICTORIA HOSPITAL   (Canada)

more..

Author keywords

coinfection; hepatic decompensation; hepatitis C; HIV; marginal structural model

Indexed keywords

ADULT; AGED; COHORT ANALYSIS; COINFECTION; COMPLICATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; LIVER FAILURE; MALE; MIDDLE AGED; PROCEDURES; VERY ELDERLY; VETERAN; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER FAILURE; MALE; MIDDLE AGED; VETERANS; YOUNG ADULT;

EID: 84894261048     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit779     Document Type: Article

References (40)

1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-96.
2. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-48.
3. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
4. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
5. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
6. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C viruscoinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
7. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-9.
8. Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related endstage liver disease. AIDS 2006; 20:49-57.
9. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035-40.
10. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-30.
11. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13.
12. Bonnard P, Lescure FX, Amiel C, et al. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. J Viral Hepat 2007; 14:806-11.
13. Collazos J, Carton JA, Asensi V. Immunological status does not influence hepatitis C virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses 2011; 27:383-9.
14. Mendes-Correa MC, Widman A, Brussi ML, Guastini CF, Gianini RJ. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil. AIDS Patient Care STDS 2008; 22:701-7.
15. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
16. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
17. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 2002; 81:213-27.
18. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) coinfected patients. J Viral Hepat 2003; 10:118-25.
19. Berenguer J, Bellon JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46:137-43.
20. Fuster D, Planas R, Muga R, et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20:1293-7.
21. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767-74.
22. Macias J, Mira JA, Lopez-Cortes LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11:839-46.
23. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41:123-31.
24. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60.
25. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006; 44(8 suppl 2):S25-30.
26. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27:274-82.
27. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-6.
28. Gandhi NR, Tate JP, Rodriguez-Barradas MC, et al. Validation of an algorithm to identify antiretroviral-naïve status at time of entry into a large, observational cohort of HIV-infected patients. Pharmacoepidemiol Drug Saf 2013; 22:1019-25.
29. McGinnis KA, Justice AC, Kraemer KL, Saitz R, Bryant KJ, Fiellin DA. Comparing alcohol screening measures among HIV infected and uninfected men. Alcohol Clin Exp Res 2013; 37:435-42.
30. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
31. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR-17):1-19.
32. Lo Re V 3rd, Lim JK, Goetz MB, et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20:689-99.
33. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-70.
34. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-64.
35. Weuve J, Tchetgen Tchetgen EJ, Glymour MM, et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology 2012; 23:119-28.
36. Sarkar M, Bacchetti P, French AL, et al. Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women. Hepatology 2012; 56:1699-705.
37. Brook G, Main J, Nelson M, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11:1-30.
38. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
39. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D Study. Arch Intern Med 2006; 166:1632-41.
40. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19:2117-25.